… BCR-ABL expression and pharmacological targeting of BCL-2, by venetoclax, alone or in
combination with BCR-ABL1 … -2 and BCR-ABL1 with venetoclax and nilotinib further increases …

… the BCR-ABL kinase. Effective against most BCR-ABL1 mutations (T315I excluded), nilotinib
… to 50-fold higher BCR/ABL kinase inhibition activity than imatinib (3). The clinical efficacy of …

… Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is
effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in …

… Nilotinib (formerly AMN107) is an orally bioavailable drug that is structurally related to …
in superior potency and selectivity for BCR-ABL [86]. Nilotinib has been used successfully in …

… at baseline, 3 had BCR-ABL1 baseline mutations (2 were … to nilotinib 13 ) in 1 patient, G250E
(sensitive to nilotinib 13 ) and … between the nilotinib C trough and the BCR-ABL1 level at 12 …

… Nilotinib (AMN-107) catalog number S1033 with molecular weight 529.52 was purchased
from Selleckchem.com, having 99.89% purity. Rapamycin (Sirolimus; 53123-88-9) and …

… nilotinib in the Asian population is scarce, particularly in Pakistan. We aimed to determine the
MR to nilotinib … Citation5 Nilotinib (Tasigna ® ) was found to be active against most imatinib-…

… The resistance to imatinib has spurred the development of several substitute drugs, such
as nilotinib (AMN107), 7 dasatinib (BMS-354825), 8 bosutinib (SKI-606), 9 etc. Flumatinib (HH-…

… This study concluded that Nilotinib treatment inhibits c-Abl activation and subsequent parkin
phosphorylation, preventing the accumulation of the toxic substrates (AIMP2). As a result, c-…

… Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically
… In this work, we found that the patients with different nilotinib responses can be classified by …